Dr Jean-Pierre Paccaud

Jean-Pierre Paccaud is since the 1st of December 2016 the Corporate Strategy and Business Development Director of the Global Antimicrobial R&D Partnership (GARDP), a joint DNDi-WHO initiative he contributed to setup and which is currently incubated within DNDi. Previously he was a member of the extended executive team of the Drugs for Neglected Diseases (DNDi), which he joined in 2007 to head the Business Development, Legal Affairs and Procurement of the foundation.

Prior to joining DNDi, Jean-Pierre founded in 2002 Athelas SA, a startup company active in the field of anti-bacterial drug discovery, which he lead until its merger with Merlion Pharmaceuticals in 2006. He continues to provide some consulting in the area for biotechs and VCs.

Before taking on entrepreneurial challenges in industry, Dr. Paccaud spent more than 18 years in academia, working in immunology, diabetes, and cell biology, and was tenured at the University of Geneva School of Medicine.

Trained as a molecular and cellular biologist, Jean-Pierre Paccaud earned his PhD at the University of Geneva School of Medicine, and completed his post-doctoral studies at the University of California at Berkeley in the laboratory of Randy Schekman.

Session 1: Antimicrobial resistance
Monday 3 April
Chairs: Professor Matthew Cooper


Supported By